View Post

Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Megan Hollasch From: onclive.com A real-world study published in the International Journal of Clinical Oncology demonstrated that most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in US community practices, which study authors noted underscores the need for timely second-line treatment. Findings from the retrospective cohort revealed that at a median follow-up of 22 months (IQR, 13-37) from …

View Post

Dr Cobain on Future Considerations For the Treatment of HR+/HER2– Breast Cancer

In In The News by Barbara Jacoby

By: Erin Cobain, MD From: onclive.com Erin Frances Cobain, MD, medical oncologist, co-director, Breast Cancer Clinical Research Team, Rogel Cancer Center, University of Michigan, discusses key takeaways derived from an OncLive Institutional Perspectives in Cancer webinar on breast cancer, highlighting patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. Investigators delved into a comprehensive array of topics surrounding breast cancer management, particularly …

View Post

PRMT5 Inhibition Stops Growth in Resistant Breast Cancer

In In The News by Barbara Jacoby

From: insideprecisionmedicine.com Scientists have learned that inhibiting the activity of the PRMT5 gene shuts down the growth of metastatic estrogen receptor-positive (ER+) breast cancer cells after they acquired resistance to therapy with CDK4/6 inhibitors. Doctors have increasingly treated metastatic ER+ breast cancers by combining drugs that degrade or block the estrogen receptors on breast cancer cells in combination with CDK4/6 inhibitors. While CDK4/6 …

View Post

Dr Nanda on the Evolution of Treatment For HER2-Low Breast Cancer

In In The News by Barbara Jacoby

By: Rita Nanda From: onclive.com Rita Nanda, MD, associate professor, medicine, director, Breast Oncology Program, University of Chicago, UChicago Medicine, discusses the evolution of treatment options for patients with HER2-low breast cancer. Nanda shares that the FDA approval of fam-trastuzumab deruxtecan-nxki(Enhertu) for patients with unresectable or metastatic HER2-low disease represents a significant milestone in oncology, Nanda begins. This regulatory decision …

View Post

Trilaciclib Advances in First-Line TNBC Treatment

In In The News by Barbara Jacoby

By: Jordyn Savap From: targetedonc.com The phase 3 PRESERVE 2 trial (NCT04799249) of trilaciclib (Cosela) in combination with gemcitabine and carboplatin for the first-line treatment of metastatic triple-negative breast cancer (TNBC) has been recommended to continue to the final analysis by the independent data monitoring committee, according to G1 Therapeutics, Inc.1 No concerns regarding safety were expressed by the data …

View Post

Exercise program improves quality of life for patients with metastatic breast cancer

In In The News by Barbara Jacoby

By: Matthew Shinkle From: healio.com Key takeaways: Results showed improved quality of life and reduced fatigue after the exercise program. More research is needed to design a safe exercise program for those with unstable bone metastases. SAN ANTONIO — Patients with metastatic breast cancer who take part in a supervised, structured exercise program during palliative treatment may experience improved quality …

View Post

Metastatic breast cancer treatments have aided decline in deaths, Stanford Medicine-led study finds

In In The News by Barbara Jacoby

By: Krista Conger From: stanford.edu Treatment of metastatic disease is responsible for nearly one-third of the decrease in annual deaths from breast cancer from 1975 to 2019, according to a Stanford Medicine-led study. Deaths from breast cancer dropped 58% between 1975 and 2019 due to a combination of screening mammography and improvements in treatment, according to a new multicenter study …

View Post

ADC Choices Require Discretion in HER2-Negative MBC

In In The News by Barbara Jacoby

By: Kyle Doherty From: onclive.com With multiple antibody drug conjugate (ADC) options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies, according to a presentation by Joshua Z. Drago, MD, MS, during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® conference.1 “ADCs are being developed …

View Post

ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: targetedonc.com CASE SUMMARY A 56-year-old, postmenopausal woman presents with a palpable right breast mass with no clinically abnormal axillary lymph nodes. Core biopsy showed the patient had grade II invasive ductal carcinoma (IDC), was estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+), and had HER2 immunohistochemistry (IHC) of 0; Ki-67 was at 33%. Lumpectomy and sentinel lymph node (SLN) biopsy showed a …

View Post

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

In In The News by Barbara Jacoby

By: By Dr. Chinta Sidharthan From: news-medical.net In a recent study published in the BMJ Journal, a team of scientists from China investigated the safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib, a pan-HER inhibitor, in combination with docetaxel and trastuzumab, and compared it to that of a variety of a …